Virttu, based in Glasgow, Scotland, is a privately-held biopharmaceutical company focused on the development of oncolytic virus therapy for treatment of cancer. Virttu's lead product candidate Seprehvir (HSV1716) is
Ezutromid dosing is expected to follow within a screening period of up to 28 days. Enrolment and dosing of patients into PhaseOut DMD in the UK is ongoing.
Guselkumab is a human monoclonal antibody with a novel mechanism of action that targets the protein interleukin (IL)-23. It is administered by subcutaneous injection. The phase 2 study
The deals provide OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform. The agreements are designed to help OSE Immunotherapeutics advance
Marinus is developing ganaxolone IV for the treatment of status epilepticus, a life-threatening medical emergency associated with high mortality and limited treatment options. The data was presented during
Albireo president and CEO Ron Cooper said: “PFIC is a highly debilitating genetic liver disorder that is life altering for affected children and their families. “There is an urgent need
Enrollment in the 60-patient open label Phase 3 trial is ongoing across multiple sites in the United States, trial completion is expected in the first half of 2017,
The programme is focused on advanced liver cancer where current chemotherapeutic treatment options are limited and the typical survival period is six months. Midatech is pursuing improved forms
LIQUENT InSight for IDMP is the newest module added to PAREXEL’s Regulatory Information Management (RIM) platform. Beginning in 2018, the European Medicines Agency (EMA) will require biopharmaceutical companies to submit
CPI-444 is a selective and potent inhibitor of the adenosine A2A receptor. The data were presented today in a poster session by John Powderly II, M.D., founder and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.